Marketing applications under review in U.S. and Europe for Vertex's CF combo tezacaftor/ivacaftor, FDA action date February 28, 2018 [Seeking Alpha]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Seeking Alpha
Vertex Pharmaceuticals ( VRTX ) announces that its marketing applications seeking approval for tezacaftor/ivacaftor for cystic fibrosis (CF) patients who have two copies of the F508del mutation or one F508del mutation and one residual function mutation that is responsive to therapy have been accepted for review by the FDA and EMA. The FDA will review the application under Priority Review status with an action date of February 28, 2018. If approved, the combo will be the company's third medication to treat CF. Now read: Flexion Therapeutics Inc.: Teeing up to disrupt the osteoarthritis market »
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies [Yahoo! Finance]Yahoo! Finance
- Vertex in-licenses cell therapy technology for diabetes candidates [Seeking Alpha]Seeking Alpha
- Global Vaccine Contract Manufacturing Market Trends Analysis Report 2024-2030: Capacity Expansion by Contract Manufacturers, & Vaccination Innovation and Robust Vaccine Pipeline Bolsters Growth [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis [Seeking Alpha]Seeking Alpha
- U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website